Orphan designation: Indole-3-carboxaldehyde Treatment of primary CTLA-4 checkpoint related immunodeficiencies, 20/03/2023 Positive | European Federation of Internal Medicine

Submitted by Anonymous (not verified) on 1 February 2024 - 9:13

Orphan designation: Indole-3-carboxaldehyde Treatment of primary CTLA-4 checkpoint related immunodeficiencies, 20/03/2023 Positive

Link:

https://www.ema.europa.eu/en/medicines/human/orphan-designations/eu-3-23-2769

Source:

Newsletters

Stay informed on our latest news!

Latest Newsletters